Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.4K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Plasma Glycoprotein Milieu in the Hemato-Oncological Patient Inhibits Platelet Function.

Biomolecules·2026
Same author

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Hematology (Amsterdam, Netherlands)·2026
Same author

The double-edged role of interferon gamma in cancer immunity.

International review of cell and molecular biology·2026
Same author

Real-World Validation of the Transplant Conditioning Intensity (TCI) Score in Allogeneic Hematopoietic Cell Transplantation: A Spanish Multicenter Study on behalf of GETH-TC.

Transplantation and cellular therapy·2026
Same author

Optimizing platelet secretome production: Impact of prostaglandin I₂ during platelet isolation on platelet activation and secretome molecular composition.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same author

Outcomes of Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis in Myelodysplastic Syndromes: A Multicenter Study Conducted on Behalf of GETH-TC.

Transplantation and cellular therapy·2026

Related Experiment Video

Updated: May 6, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K

Lenalidomide and chronic lymphocytic leukemia.

Ana Pilar González-Rodríguez1, Angel R Payer, Andrea Acebes-Huerta

  • 1Department of Hematology, Hospital Universitario Central de Asturias, C/Celestino Villamil s/n, 33006 Oviedo, Spain.

Biomed Research International
|October 29, 2013
PubMed
Summary

Lenalidomide shows promise in treating chronic lymphocytic leukemia (CLL) by restoring immune surveillance. Its unique toxic effects, like tumor lysis syndrome, require specific management strategies in CLL patients.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.0K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

10.3K

Related Experiment Videos

Last Updated: May 6, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

23.7K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.0K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

10.3K

Area of Science:

  • Oncology
  • Immunology

Background:

  • Lenalidomide is an immunomodulatory drug approved for multiple myeloma and myelodysplastic syndrome.
  • It has demonstrated efficacy in treating lymphoproliferative disorders, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma.

Purpose of the Study:

  • To review the mechanism of action of lenalidomide in CLL.
  • To discuss the efficacy of lenalidomide, alone or in combination, for CLL treatment.
  • To highlight the unique toxic effects of lenalidomide in CLL, such as tumor lysis syndrome and tumor flare reaction.

Main Methods:

  • Literature review of studies on lenalidomide in CLL.
  • Analysis of lenalidomide's mechanism of action in the context of CLL.
  • Evaluation of clinical efficacy data and safety profiles.

Main Results:

  • Lenalidomide appears to restore tumor immunosurveillance mechanisms in CLL.
  • Efficacy data for lenalidomide, as monotherapy and in combination, are emerging for CLL.
  • Specific toxicities, including tumor lysis syndrome (TLS) and tumor flare reaction (TFR), necessitate distinct management approaches.

Conclusions:

  • Lenalidomide presents a potential therapeutic option for CLL by enhancing anti-tumor immunity.
  • Understanding and managing lenalidomide-associated toxicities are crucial for its safe and effective use in CLL.
  • Further research is warranted to optimize lenalidomide-based therapies for CLL.